Therapeutic nanosystems for oncology nanomedicine

Clinical and Translational Oncology

Volumn 14, Issue 12, 2012, Pages 883-890

  Goncalves A S ^a   Macedo, A S ^a   Souto, E B ^a,b  

^a UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^b Centre of Genomics and Biotechnology   (Portugal)

Author keywords

Anticancer chemotherapy; Biosensors; Brain cancer; Breast cancer; Cancer; Cancer biomarkers; Colorectal cancer; Lung cancer; Magnetic resonance imaging; Nanomedicine; Nanoparticles; Nanotechnology; Theranostics

Indexed keywords

ABRAXENE; CARBOPLATIN; CHITOSAN; CISPLATIN; CURCUMIN; DOCETAXEL; DOXORUBICIN; EDELFOSINE; ERLOTINIB; FLUOROURACIL; GEMCITABINE; GOLD NANOPARTICLE; HYALURONIC ACID; IFOSFAMIDE; IRINOTECAN; LIPOSOME; LONIDAMINE; MACROGOL; NANOPARTICLE; OXALIPLATIN; PACLITAXEL; PEMETREXED; POLYETHYLENEIMINE; POLYMER; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CHEMORADIOTHERAPY; COLORECTAL CANCER; DRUG ACCUMULATION; DRUG EFFICACY; DRUG TARGETING; DRUG TRANSPORT; HUMAN; INTRACELLULAR TRANSPORT; LIPOSOMAL DELIVERY; LUNG CANCER; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; NANOMEDICINE; NONHUMAN; TUMOR INVASION;

EID: 84875178186     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0912-1     Document Type: Article

References (84)

1. WHO (2010) Global status report on NCDs (cited 13-03-2012). http://www.who.int/gho/ncd/mortality-morbidity/cancer-text/en/index.html
2. Misra R, Acharya S, Sahoo SK (2010) Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov Today 15(19-20):842-850
3. Ullah MF, Aatif M (2009) The footprints of cancer development: cancer biomarkers. Cancer Treat Rev 35(3):193-200
4. Veiseh O, Kievit FM, Ellenbogen RG, Zhang M (2011) Cancer cell invasion: treatment and monitoring opportunities in nanomedicine. Adv Drug Deliv Rev 63(8):582-596
5. Lee K, Lee H, Bae KH, Park TG (2010) Heparin immobilized gold nanoparticles for targeted detection and apoptotic death of metastatic cancer cells. Biomaterials 31(25):6530-6536
6. Leong A, Zhuang Z, Badawi A (2011) The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology 79:99-118
7. Haley B, Frenkel E (2008) Nanoparticles for drug delivery in cancer treatment. Urol Oncol Semin Orig Investig 26(1):57-64
8. Manthe R, Foy S, Krishnamurthy N, Sharma B, Labhasetwar V (2010) Tumor ablation and nanotechnology. Mol Pharm 7(6):1880-1898
9. Wang M, Thanou M (2010) Targeting nanoparticles to cancer. Pharmacol Res 62(2):90-99
10. Bhattacharya R, Mukherjee P (2008) Biological properties of "naked" metal nanoparticles. Adv Drug Deliv Rev 60(11):1289-1306
11. Marcucci F, Corti A (2012) How to improve exposure of tumor cells to drugs - promoter drugs increase tumor uptake and penetration of effector drugs. Adv Drug Deliv Rev 64(1):53-68
12. Garcia-Bennett A, Nees M, Fadeel B (2011) In search of the Holy Grail: folate-targeted nanoparticles for cancer therapy. Biochem Pharmacol 81(8):976-984
13. Leite de Oliveira R, Hamm A, Mazzone M (2011) Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. Mol Aspects Med 32(2):71-87
14. Bridges EM, Harris AL (2011) The angiogenic process as a therapeutic target in cancer. Biochem Pharmacol 81(10):1183-1191
15. Weiss A, van den Bergh H, Griffioen AW, Nowak-Sliwinska P (2012) Angiogenesis inhibition for the improvement of photodynamic therapy: The revival of a promising idea. Biochim Biophys Acta 1826(1):53-70
16. Li Y, Wang J, Wientjes MG, Au JLS (2012) Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev 64(1):29-39
17. Grobmyer SR, Zhou G, Gutwein LG, Iwakuma N, Sharma P, Hochwald SN (2012) Nanoparticle delivery for metastatic breast cancer. Maturitas [Epub ahead of print]
18. Ema M, Tanaka J, Kobayashi N, Naya M, Endoh S, Maru J et al (2012) Genotoxicity evaluation of fullerene C60 nanoparticles in a comet assay using lung cells of intratracheally instilled rats. Regul Toxicol Pharmacol 62(3):419-424
19. Cuenca A, Jiang H, Hochwald S, Delano M, Cance W, Grobmyer S (2006) Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer 107(3):459-466
20. Cormode DP, Jarzyna PA, Mulder WJM, Fayad ZA (2010) Modified natural nanoparticles as contrast agents for medical imaging. Adv Drug Deliv Rev 62(3):329-338
21. Peter M, Binulal NS, Soumya S, Nair SV, Furuike T, Tamura H et al (2010) Nanocomposite scaffolds of bioactive glass ceramic nanoparticles disseminated chitosan matrix for tissue engineering applications. Carbohydr Polym 79(2):284-289
22. Pagni G, Kaigler D, Rasperini G, Avila-Ortiz G, Bartel R, Giannobile WV (2012) Bone repair cells for craniofacial regeneration. Adv Drug Deliv Rev [Epub ahead of print]
23. Cháfer-Pericás C, Maquieira A, Puchades R (2012) Functionalized inorganic nanoparticles used as labels in solid-phase immunoassays. Trends Anal Chem 31:144-156
24. Prakash S, Malhotra M, Shao W, Tomaro-Duchesneau C, Abbasi S (2011) Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy. Adv Drug Deliv Rev 63(14-15):1340-1351
25. Xiao Y, Hong H, Javadi A, Engle JW, Xu W, Yang Y et al (2012) Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials 33(11):3071-3082
26. Koning GA, Krijger GC (2007) Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery. Anti Cancer Agents Med Chem 7:425-440
27. Gong J, Jaiswal R, Mathys JM, Combes V, Grau GER, Bebawy M (2012) Microparticles and their emerging role in cancer multidrug resistance. Cancer Treat Rev 38(3):226-234
28. Kang KW, Chun M-K, Kim O, Subedi RK, Ahn S-G, Yoon J-H et al (2010) Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomed Nanotechnol Biol Med 6(2):210-213
29. Shapira A, Livney YD, Broxterman HJ, Assaraf YG (2011) Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat 14(3):150-163
30. Parveen S, Misra R, Sahoo SK (2012) Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomed Nanotechnol Biol Med 8(2):147-166
31. Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5(4):505-515
32. Owens Iii DE, Peppas NA (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307(1):93-102
33. Liechty WB, Peppas NA (2012) Expert opinion: responsive polymer nanoparticles in cancer therapy. Eur J Pharm Biopharm 80(2):241-246
34. Danhier F, Feron O, Préat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Controlled Release 148(2):135-146
35. Byrne JD, Betancourt T, Brannon-Peppas L (2008) Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60(15):1615-1626
36. Yang T, Choi M-K, Cui F-D, Kim JS, Chung S-J, Shim C-K et al (2007) Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Controlled Release 120(3):169-177
37. Krieger ML, Eckstein N, Schneider V, Koch M, Royer H-D, Jaehde U et al (2010) Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro. Int J Pharm 389(1-2):10-17
38. Wang Y, Yu L, Han L, Sha X, Fang X (2007) Difunctional Pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines. Int J Pharm 337(1-2):63-73
39. Szebeni J, Bedocs P, Urbanics R, Bünger R, Rosivall L, Tóth M et al (2012) Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model. J Controlled Release 160(2):382-387
40. Meng J, Fan J, Galiana G, Branca RT, Clasen PL, Ma S et al (2009) LHRH-functionalized superparamagnetic iron oxide nanoparticles for breast cancer targeting and contrast enhancement in MRI. Mater Sci Eng C 29(4):1467-1479
41. Davies E, Hiscox S (2011) New therapeutic approaches in breast cancer. Maturitas 68:121-128
42. Yallapu MM, Othman SF, Curtis ET, Gupta BK, Jaggi M, Chauhan SC (2011) Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy. Biomaterials 32(7):1890-1905
43. Milane L, Duan Z-f, Amiji M (2011) Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer. Nanomed Nanotechnol Biol Med 7(4):435-444
44. Burke AR, Singh RN, Carroll DL, Wood JCS, D'Agostino RB Jr, Ajayan PM et al (2012) The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy. Biomaterials 33(10):2961-2970
45. McCarthy HO, Zholobenko AV, Wang Y, Canine B, Robson T, Hirst DG et al (2011) Evaluation of a multi-functional nanocarrier for targeted breast cancer iNOS gene therapy. Int J Pharm 405(1-2):196-202
46. Aliabadi HM, Landry B, Mahdipoor P, Hsu CYM, Uludaǧ H (2012) Effective down-regulation of Breast Cancer Resistance Protein (BCRP) by siRNA delivery using lipid-substituted aliphatic polymers. Eur J Pharm Biopharm 81(1):33-42
47. Hun X, Zhang Z (2009) Anti-epidermal growth factor receptor (anti-EGFR) antibody conjugated fluorescent nanoparticles probe for breast cancer imaging. Spectrochim Acta Part A Mol Biomol Spectrosc 74(2):410-414
48. Tomoda K, Ohkoshi T, Hirota K, Sonavane GS, Nakajima T, Terada H et al (2009) Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. Colloids Surf B 71(2):177-182
49. Mylonakis N, Athanasiou A, Ziras N, Angel J, Rapti A, Lampaki S et al (2010) Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer 68(2):240-247
50. Zhang W, Shi Y, Chen Y, Yu S, Hao J, Luo J et al (2010) Enhanced antitumor efficacy by Paclitaxel-loaded Pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. Eur J Pharm Biopharm 75(3):341-353
51. Azarmi S, Roa WH, Löbenberg R (2008) Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev 60(8):863-875
52. Roa WH, Azarmi S, Al-Hallak MHDK, Finlay WH, Magliocco AM, Löbenberg R (2011) Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J Controlled Release 150(1):49-55
53. Barash O, Peled N, Tisch U, Bunn Jr PA, Hirsch FR, Haick H (2011) Classification of lung cancer histology by gold nanoparticle sensors. Nanomedicine 8(5):580-589
54. He F, Shen Q, Jiang H, Zhou J, Cheng J, Guo D et al (2009) Rapid identification and high sensitive detection of cancer cells on the gold nanoparticle interface by combined contact angle and electrochemical measurements. Talanta 77(3):1009-1014
55. Sarfati G, Dvir T, Elkabets M, Apte RN, Cohen S (2011) Targeting of polymeric nanoparticles to lung metastases by surface-attachment of YIGSR peptide from laminin. Biomaterials 32(1):152-161
56. Nafee N, Schneider M, Friebel K, Dong M, Schaefer UF, Mürdter TE et al (2012) Treatment of lung cancer via telomerase inhibition: self-assembled nanoplexes versus polymeric nanoparticles as vectors for 2′-O-methyl-RNA. Eur J Pharm Biopharm 80(3):478-489
57. Zou W, Liu C, Chen Z, Zhang N (2009) Studies on bioadhesive PLGA nanoparticles: a promising gene delivery system for efficient gene therapy to lung cancer. Int J Pharm 370(1-2):187-195
58. Choi SH, Jin S-E, Lee M-K, Lim S-J, Park J-S, Kim B-G et al (2008) Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. Eur J Pharm Biopharm 68(3):545-554
59. Taetz S, Nafee N, Beisner J, Piotrowska K, Baldes C, Mürdter TE et al (2009) The influence of chitosan content in cationic chitosan/PLGA nanoparticles on the delivery efficiency of antisense 2′-O-methyl-RNA directed against telomerase in lung cancer cells. Eur J Pharm Biopharm 72(2):358-369
60. Chittasupho C, Xie S-X, Baoum A, Yakovleva T, Siahaan TJ, Berkland CJ (2009) ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur J Pharm Sci 37(2):141-150
61. Yang S-J, Shieh M-J, Lin F-H, Lou P-J, Peng C-L, Wei M-F et al (2009) Colorectal cancer cell detection by 5-aminolaevulinic acid-loaded chitosan nano-particles. Cancer Lett 273(2):210-220
62. Sakuma S, Yano T, Masaoka Y, Kataoka M, Ken-ichiro H, Tachikawa H et al (2009) In vitro/in vivo biorecognition of lectin-immobilized fluorescent nanospheres for human colorectal cancer cells. J Controlled Release 134(1):2-10
63. Sakuma S, Yano T, Masaoka Y, Kataoka M, Hiwatari K-I, Tachikawa H et al (2010) Detection of early colorectal cancer imaged with peanut agglutinin-immobilized fluorescent nanospheres having surface poly(N-vinylacetamide) chains. Eur J Pharm Biopharm 74(3):451-460
64. Cho Y-S, Yoon T-J, Jang E-S, Soo Hong K, Young Lee S, Ran Kim O et al (2010) Cetuximab-conjugated magneto-fluorescent silica nanoparticles for in vivo colon cancer targeting and imaging. Cancer Lett 299(1):63-71
65. Tao L, Zhang K, Sun Y, Jin B, Zhang Z, Yang K (2012) Anti-epithelial cell adhesion molecule monoclonal antibody conjugated fluorescent nanoparticle biosensor for sensitive detection of colon cancer cells. Biosens Bioelectron 35(1):186-192
66. Li ZJ, Wu WKK, Ng SSM, Yu L, Li HT, Wong CCM et al (2010) A novel peptide specifically targeting the vasculature of orthotopic colorectal cancer for imaging detection and drug delivery. J Controlled Release 148(3):292-302
67. Löw K, Wacker M, Wagner S, Langer K, von Briesen H (2011) Targeted human serum albumin nanoparticles for specific uptake in EGFR-Expressing colon carcinoma cells. Nanomed Nanotechnol Biol Med 7(4):454-463
68. Chow T-H, Lin Y-Y, Hwang J-J, Wang H-E, Tseng Y-L, Pang VF et al (2008) Diagnostic and therapeutic evaluation of 111In-vinorelbine-liposomes in a human colorectal carcinoma HT-29/luc-bearing animal model. Nucl Med Biol 35(5):623-634
69. Jain A, Jain SK, Ganesh N, Barve J, Beg AM (2010) Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomed Nanotechnol Biol Med 6(1):179-190
70. Sun N-F, Meng Q-Y, Tian A-L, Hu S-Y, Wang R-H, Liu Z-X et al (2012) Nanoliposome-mediated FL/TRAIL double-gene therapy for colon cancer: in vitro and in vivo evaluation. Cancer Lett 315(1):69-77
71. Wong HL, Wu XY, Bendayan R (2012) Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 64(7):686-700
72. Orive G, Ali OA, Anitua E, Pedraz JL, Emerich DF (2010) Biomaterial-based technologies for brain anti-cancer therapeutics and imaging. Biochim Biophys Acta Rev Cancer 1806(1):96-107
73. Venishetty VK, Komuravelli R, Kuncha M, Sistla R, Diwan PV (2012) Increased brain uptake of docetaxel- and ketoconazole-loaded folate-grafted solid lipid nanoparticles. Nanomed Nanotechnol Biol Med [Epub ahead of print]
74. Kaur IP, Bhandari R, Bhandari S, Kakkar V (2008) Potential of solid lipid nanoparticles in brain targeting. J Controlled Release 127(2):97-109
75. Weiss N, Miller F, Cazaubon S, Couraud P-O (2009) The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta Biomembr 1788(4):842-857
76. Blasi P, Giovagnoli S, Schoubben A, Puglia C, Bonina F, Rossi C et al (2011) Lipid nanoparticles for brain targeting I. Formulation optimization. Int J Pharm 419(1-2):287-295
77. Wohlfart S, Gelperina S, Kreuter J (2012) Transport of drugs across the blood-brain barrier by nanoparticles. J Controlled Release 161(2):264-273
78. Rempe R, Cramer S, Hüwel S, Galla H-J (2011) Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity. Biochem Biophys Res Commun 406(1):64-69
79. Kuo Y-C, Liang C-T (2011) Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells. Colloids Surf B 85(2):131-137
80. Kuo Y-C, Liang C-T (2011) Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials 32(12):3340-3350
81. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C (2007) Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 59(6):454-477
82. Martins S, Tho I, Souto E, Ferreira D, Brandl M (2012) Multivariate design for the evaluation of lipid and surfactant composition effect for optimisation of lipid nanoparticles. Eur J Pharm Sci 45(5):613-623
83. Estella-Hermoso de Mendoza A, Préat V, Mollinedo F, Blanco-Prieto MJ (2011) In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J Controlled Release 156(3):421-426
84. Kundu P, Mohanty C, Sahoo SK (2012) Antiglioma activity of curcumin loaded lipid nanoparticles and its enhanced bioavailability in brain tissue for effective glioblastoma therapy. Acta Biomater 8(7):2670-2687